The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone

DeFronzo, Ralph A., Hissa, Miguel N., Garber, Alan J., Luiz Gross, Jorge, Yuyan Duan, Raina, Ravichandran, Shoba, Chen, Roland S., for the Saxagliptin 014 Study Group·2009·Diabetes Care
DOI 10.2337/dc08-1984

Cited by (415)

Items 201–300 of 415

  1. Relationship of the Serum CRP Level With the Efficacy of Metformin in the Treatment of Type 2 Diabetes Mellitus: A Meta‐Analysis
    Lei Shi, Guang‐Shan Tan, Kun Zhang · 2014 · Journal of Clinical Laboratory Analysis
  2. Saxagliptin, a potent, selective inhibitor of DPP‐4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects
    Chirag G. Patel, David M. Kornhauser, N. Vachharajani, Bernard J. Komoroski, E. Brenner, M. Handschuh del Corral, L. Li, David W. Boulton · 2011 · Diabetes Obesity and Metabolism
  3. The Intersection of Safety and Adherence: New Incretin‐Based Therapies in Patients with Type 2 Diabetes Mellitus
    Barbara J.M. Zarowitz, Christopher Conner · 2009 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  4. The long‐term efficacy and safety of DPP‐IV inhibitors monotherapy and in combination with metformin in 18 980 patients with type‐2 diabetes mellitus—a meta‐analysis
    Xia Liu, Qian Xiao, Li Zhang, Qiao Yang, Xiaoyan Liu, Lingjie Xu, Wen Jun Cheng · 2014 · Pharmacoepidemiology and Drug Safety
  5. Diabetes: glycaemic control in type 2 (drug treatments).
    Kees J. Gorter, Floris A Van de Laar, P. G. H. Janssen, Sebastiaan T. Houweling, Guy E.H.M. Rutten · 2012 · Europe PMC (PubMed Central)
  6. Liraglutide in oral antidiabetic drug combination therapy
    Alan J. Garber · 2012 · Diabetes Obesity and Metabolism
  7. Metformin + saxagliptin for type 2 diabetes
    André Jacques Scheen · 2011 · Expert Opinion on Pharmacotherapy
  8. Focus on Incretin-Based Therapies: Targeting the Core Defects of Type 2 Diabetes
    Paul S. Jellinger · 2011 · Postgraduate Medicine
  9. Incretin-Based Therapies in Complex Patients: Practical Implications and Opportunities for Maximizing Clinical Outcomes: A Discussion with Dr. Vivian A. Fonseca
    Vivian Andrew Fonseca · 2010 · The American Journal of Medicine
  10. Add-on therapies to metformin for type 2 diabetes
    Mansur E. Shomali · 2010 · Expert Opinion on Pharmacotherapy
  11. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes
    Mikaela Sjöstrand, Nayyar Iqbal, Jane Lu, Boaz Hirshberg · 2014 · Diabetes Research and Clinical Practice
  12. Evolving Metformin Treatment Strategies in Type-2 Diabetes
    Antônio Roberto Chacra · 2012 · American Journal of Therapeutics
  13. Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial
    Tina Vilsbøll, Ella Ekholm, EVA K. JOHNSSON, Nalina Dronamraju, Serge A Jabbour, Marcus Lind · 2019 · Diabetes Care
  14. Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis
    Shubing Jia, Zhiying Wang, Ruobing Han, Zinv Zhang, Yuping Li, Xiaotong Qin, Mingyi Zhao, Rongwu Xiang, Jingyu Yang · 2020 · Acta Diabetologica
  15. Evolving Treatment Strategies for the Management of Type 2 Diabetes
    William T. Cefalu · 2011 · The American Journal of the Medical Sciences
  16. AHRQ’s Comparative Effectiveness Research on Oral Medications for Type 2 Diabetes: A Summary of the Key Findings
    Wendy L. Bennett, Lisa M. Balfe, Joanne M. Faysal · 2012 · Journal of Managed Care Pharmacy
  17. Efficacy and Safety of Saxagliptin Combination Therapy in US Patients with Type 2 Diabetes
    Chetan S. Karyekar, Mark Donovan, Elsie Allen, Douglas Fleming, Shoba Ravichandran, Roland K. Chen · 2011 · Postgraduate Medicine
  18. International Diabetes Center Treatment of Type 2 Diabetes Glucose Algorithm
    Gregg Simonson, Robert M Cuddihy, Diane Reader, Richard M. Bergenstal · 2011 · Diabetes Management
  19. Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes
    Rose Anderson, Jennifer Hayes, Jeffrey Wayne Stephens · 2016 · Expert Opinion on Drug Metabolism & Toxicology
  20. Individualized homeopathic treatment in addition to conventional treatment in type II diabetic patients in Hong Kong – a retrospective cohort study
    Ka Lun Aaron To, Yvonne Fok, Ka Chun Chong, Yuen Chi Joanne Lee, Ling Shan Sandy Yiu · 2017 · Homeopathy
  21. Meta-Analysis of the Cardiovascular Outcomes with Dipeptidyl Peptidase 4 Inhibitors: Validation of the Current FDA Mandate
    Shikhar Agarwal, Akhil Parashar, Venu Menon · 2014 · American Journal of Cardiovascular Drugs
  22. Pharmacological management of diabetes in severe mental illness: a comprehensive clinical review of efficacy, safety and tolerability
    John Lally, Aonghus O’ Loughlin, Brendon Stubbs, Allys Guérandel, Donal Brendan O'Shea, Fiona Gaughran · 2018 · Expert Review of Clinical Pharmacology
  23. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus
    Robert M. Guthrie · 2015 · Postgraduate Medicine
  24. Incretin-Based Therapies: Focus on Effects Beyond Glycemic Control Alone
    Jaime A. Davidson · 2013 · Diabetes Therapy
  25. Analysis of Patents Issued in China for Antihyperglycemic Therapies for Type 2 Diabetes Mellitus
    Wei Jian Zhu, Wen R. H. Huang, Zhiqiang Xu, Mengda Cao, Qiaoli Hu, Pan Chen, Miao Guo, Ji‐Fu Wei, Hongyu Yuan · 2019 · Frontiers in Pharmacology
  26. Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China
    Shuyan Gu, Jing Deng, Lizheng Shi, Yiming Mu, Hengjin Dong · 2015 · Journal of Medical Economics
  27. Clinically relevant reductions in HbA 1c without hypoglycaemia: results across four studies of saxagliptin
    Chetan S. Karyekar, Robert C. Frederich, Shivakumar Ravichandran · 2013 · International Journal of Clinical Practice
  28. Saxagliptin as initial therapy in treatment-naive Indian adults with type 2 diabetes mellitus inadequately controlled with diet and exercise alone: a randomized, double-blind, placebo-controlled, phase IIIb clinical study
    K.M. PRASANNA KUMAR, Sunil M. Jain, Conrad Tou, Kajs-Marie Schützer · 2014 · International Journal of Diabetes in Developing Countries
  29. Comparative efficacy and safety of glucose-lowering drugs in children and adolescents with type 2 diabetes: A systematic review and network meta-analysis
    Sijia Wu, Yina He, Yutong Wu, Yiman Ji, Lei Hou, Xinhui Liu, Yilei Ge, Yuanyuan Yu, Yifan Yu, Yun Wei et al. · 2022 · Frontiers in Endocrinology
  30. Pharmacokinetic Study of Saxagliptin in Healthy Chinese Subjects
    Haiyan Li, Yang Li, Conrad Tou, Chirag G. Patel, June Zhao · 2012 · Clinical Drug Investigation
  31. Management of patients with type 2 diabetes
    Scott E. Nelson · 2011 · Current Medical Research and Opinion
  32. Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes
    Feng-fei Li, Lanlan Jiang, Rengna Yan, Honghong Zhu, Peihua Zhou, Danfeng Zhang, Xiaofei Su, Jin-dan Wu, Lei Ye, Jianhua Ma · 2016 · Medicine
  33. Effects of saxagliptin on glucose homeostasis and body composition of obese patients with newly diagnosed pre-diabetes
    Zixuan Wang, Dengcheng Xu, Lanhui Huang, Tiantian Zhang, Junqiao Wang, Qing Chen, Lei Kong, Xinli Zhou · 2017 · Diabetes Research and Clinical Practice
  34. Utilizing Current Diagnostic Criteria and Treatment Algorithms for Managing Type 2 Diabetes Mellitus
    Davida F. Kruger, Jackie L. Boucher, Mary Ann Banerji · 2011 · Postgraduate Medicine
  35. The Role of Self-Monitoring of Blood Glucose in Glucagon-like Peptide-1-Based Treatment Approaches: A European Expert Recommendation
    Oliver Schnell, Hasan Alawi, Tadej Battelino, Antonio Ceriello, Peter Diem, Anne-Marie Felton, Władysław Grzeszczak, Kari Harno, Péter Kempler, İlhan Satman et al. · 2012 · Journal of Diabetes Science and Technology
  36. The design of the liraglutide clinical trial programme
    Michael Albrecht Nauck · 2012 · Diabetes Obesity and Metabolism
  37. Liraglutide: effects beyond glycaemic control in diabetes treatment
    Janet B. McGill · 2010 · International Journal of Clinical Practice
  38. Comparative evaluation of incretin‐based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure†
    Michael Albrecht Nauck, Irfan Vardarli · 2010 · Journal of Diabetes Investigation
  39. A linearization approach for the model‐based analysis of combined aggregate and individual patient data
    Patanjali Ravva, Mats O. Karlsson, Jonathan L French · 2014 · Statistics in Medicine
  40. DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
    Erna Kristin · 2016 · Journal of the Medical Sciences (Berkala Ilmu Kedokteran)
  41. Reshaping Diabetes Care: The Fundamental Role of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Clinical Practice
    Guillermo E. Umpierrez, Luigi Meneghini · 2013 · Endocrine Practice
  42. Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, Phase 3 trial
    Tina Vilsbøll, Ella Ekholm, EVA K. JOHNSSON, Ricardo García‐Sánchez, Nalina Dronamraju, Serge A Jabbour, Marcus Lind · 2020 · Diabetes Obesity and Metabolism
  43. Glucose‐lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase‐4 inhibition
    Bo Åhrén · 2021 · Journal of Diabetes Investigation
  44. Efficacy and safety of DBPR108 (prusogliptin) as an add‐on to metformin therapy in patients with type 2 diabetes: A 24‐week, multi‐centre, randomized, double‐blind, placebo‐controlled, superiority, phase III clinical trial
    Jianping Xu, Hongwei Ling, Jianlin Geng, Investigators, Yanli Huang, Ying Xie, Huiping Zheng, Huikun Niu, Tianhao Zhang, Jing Yuan et al. · 2022 · Diabetes Obesity and Metabolism
  45. Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes
    Morali D. Sharma, Garber · 2010 · Therapeutics and Clinical Risk Management
  46. Incretin-Related Therapies in Type 2 Diabetes: A Practical Overview
    Carolyn Robertson · 2011 · Diabetes Spectrum
  47. Metformin Combinatorial Therapy for Type 2 Diabetes Mellitus
    Keerthi Kupsal, Saraswati Mudigonda, Sai NVBK, Krishnaveni Neelala · 2016 · Journal of Metabolic Syndrome
  48. Recent and Emerging Therapeutic Medications in Type 2 Diabetes Mellitus
    Margaret C. Lo, Maria Cecilia Lansang · 2010 · American Journal of Therapeutics
  49. Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
    Huan Ju Yu, Vincent C. Woo · 2017 · Diabetes Metabolic Syndrome and Obesity
  50. Oral Anti-Diabetic Agents-Review and Updates
    Patience Ogoamaka Osadebe, Estella Odoh, Philip F. Uzor · 2014 · Journal of Advances in Medicine and Medical Research
  51. Diabetes Treatment: Oral Agents
    Michael J. Fowler · 2010 · Clinical Diabetes
  52. Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes
    Clifford J. Bailey, Stefano Del Prato, Cheryl Wei, Daniel Reyner, Gabriela Luporini Saraiva · 2019 · Diabetes Obesity and Metabolism
  53. Comparative Efficacy of Dual and Single Initiation of Add-On Oral Antihyperglycemic Agents in Type 2 Diabetes Uncontrolled on Metformin Alone: A Systematic Literature Review and Network Meta-Analysis
    Dominik Lautsch, Adnan Alsumali, Euan James McLeod, Yuting Kuang, Jing Na He, Rajpal Singh, Arianna Nevo, Urs A. Arnet, Jennifer Uyei, Swapnil N. Rajpathak · 2020 · Diabetes Therapy
  54. Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease
    Siew Hwa Ong, Matthias Blüher, Andy Schuetz · 2015 · ClinicoEconomics and Outcomes Research
  55. Saxagliptin for type 2 diabetes
    Chacra · 2010 · Diabetes Metabolic Syndrome and Obesity
  56. Incretin-based Therapy in Chronic Kidney Disease
    Nicole R. Pinelli, Carol L. Moore, Sarah Tomasello · 2010 · Advances in Chronic Kidney Disease
  57. Type 2 Diabetes in Adults
    2011 · Wiley eBooks
  58. Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus.
    Alan J. Garber · 2011 · PubMed
  59. Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease History or Cardiovascular Risk Factors: Results of a Pooled Analysis of Phase 3 Clinical Trials
    W. James Cook, Brian S. Bryzinski, Jill Slater, Robert C. Frederich, Elsie Allen · 2013 · Postgraduate Medicine
  60. Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Combination with Metformin
    Andrea D. Fass, Jennifer A. Gershman · 2013 · Advances in Therapy
  61. Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugs.
    Jeffrey S. Freeman · 2010 · PubMed
  62. Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease
    Peter Paul Toth · 2014 · Vascular Health and Risk Management
  63. Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials
    George Grunberger · 2014 · European Journal of Clinical Pharmacology
  64. Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions
    Kayo Fujita, Masayuki Kaneko, Mamoru Narukawa · 2016 · Clinical Drug Investigation
  65. Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials
    Mikaela Sjöstrand, Cheryl Wei, William Cook, Kristina M. Johnsson, Pia S. Pollack, Christina Stahre, Boaz Hirshberg · 2017 · Diabetes Therapy
  66. Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus
    Kazuki Orime, Yasuo Terauchi · 2020 · Expert Opinion on Pharmacotherapy
  67. Genetic regulation of male sexual development in the oriental river prawn Macrobrachium nipponense during reproductive vs. non-reproductive season
    Shubo Jin, Wenyi Zhang, Yiwei Xiong, Sufei Jiang, Hui Qiao, Yongsheng Gong, Yanyou Wu, Hongtuo Fu · 2022 · Aquaculture International
  68. Reaching HbA1cGoals with Saxagliptin in Combination with Other Oral Antidiabetic Drugs
    James R. LaSalle · 2010 · Postgraduate Medicine
  69. Efficacy and safety of saxagliptin monotherapy or added to metformin in Chinese patients with type 2 diabetes mellitus: results from the 24‐week, post‐marketing SUNSHINE study
    Weiqiong Gu, Liang Li, Shengxiang Wang, Yunzhi Wang, Yanxiang Wu, Jian Tian, Gangyi Yang, Chunli Piao, Yuzhong Li, Jianmei Yin et al. · 2015 · Journal of Diabetes
  70. Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey – GALATA study
    Göksün Ayvaz, Lezzan Keskin, Fulya Akın, Hatice Sebila Dökmetaş, Ertuğrul Taşan, İdilhan Ar, Emel Uren, GALATA Study Group · 2015 · Current Medical Research and Opinion
  71. Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors
    Bo Åhrén · 2013 · European Diabetes Nursing
  72. Saxagliptin
    Sum Lam, Maha Saad · 2010 · Cardiology in Review
  73. Efficacy and Safety of Saxagliptin as Add-On Therapy in Type 2 Diabetes
    Joshua J. Neumiller · 2014 · Clinical Diabetes
  74. Clinical overview of saxagliptin for Type 2 diabetes management
    Julio Rosenstock · 2010 · Expert Review of Endocrinology & Metabolism
  75. Adverse drug reaction monitoring of newer oral anti diabetic drugs a pharmacovigilance perspective
    Ankita Bhattacharjee, M. C. Gupta, Sameer Agrawal · 2016 · International Journal of Pharmacological Research
  76. Prevalence and Predictors of Metformin Prescribing in Adults with Type 2 Diabetes Mellitus: A National Cross‐Sectional Study
    Mate Michael Soric, John Michael Moorman, Jaclyn A. Boyle, Samuel D. Crish · 2016 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  77. Efficacy, safety and impact on β-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis
    Weiyi Gao, Q. Wang, Sufang Yu · 2016 · Journal of Endocrinological Investigation
  78. Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013 (新型2型糖尿病治疗药物：第2部分. 2013年临床上针对肠促胰岛素缺陷的治疗药物)
    George Grunberger · 2013 · Journal of Diabetes
  79. New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
    Baptist Gallwitz · 2010 · Diabetes Metabolic Syndrome and Obesity
  80. Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination
    John Doupis, George S. Panagoulias · 2014 · Patient Preference and Adherence
  81. A systematic review of the safety of incretin-based therapies in type 2 diabetes
    Marc Evans, Stephen Charles Bain, Jiten P Vora · 2016 · Expert Review of Endocrinology & Metabolism
  82. Saxagliptin
    Etzel Gysling · 2010 · pharma-kritik
  83. Systematic Review and Network Meta-analysis to Compare Dapagliflozin with other Diabetes Medications in Combination with Metformin for Adults with Type 2 Diabetes
    Barnett Ah, Orme ME · 2014 · Internal Medicine Open Access
  84. NOVEL RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF SAXAGLIPTIN AND GLIMEPIRIDE
    Navneet Kumar Upadhyay, Charul Rathore, Sameer Sapra, Poonam Negi · 2018 · International Journal of Applied Pharmaceutics
  85. Clinical Pharmacology of Dipeptidyl Peptidase 4 Inhibitors: Comparative Review
    A. V. Sidorov · 2020 · Effective Pharmacotherapy
  86. Managing Type 2 Diabetes in the Primary Care Setting: Beyond Glucocentricity
    Louis Kuritzky · 2010 · The American Journal of the Medical Sciences
  87. Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system
    Marcelo Eidi Nita, Freddy Goldberg Eliaschewitz, Eliane Ribeiro, Elio Fernando Asano, Elias Barbosa, Maíra Libertad Soligo Takemoto, Bonnie M.K. Donato, Roberto Del Valhe Abi Rached, Elaine Rahal · 2012 · Revista da Associação Médica Brasileira
  88. Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta‐analysis
    Sanaz Kamalinia, Robert G. Josse, Patrick J. Donio, Lindsay Leduc, Baiju R. Shah, Sheldon W. Tobe · 2019 · Endocrinology Diabetes & Metabolism
  89. Therapeutic Options that Provide Glycemic Control and Weight Loss for Patients with Type 2 Diabetes
    Thomas Blevins · 2010 · Postgraduate Medicine
  90. Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes
    Stanley S. Schwartz · 2014 · Postgraduate Medicine
  91. Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs
    M. Elle Saine, Dena M. Carbonari, Craig W. Newcomb, Melissa S. Nezamzadeh, Kevin Haynes, Jason A. Roy, Serena Cardillo, Sean Hennessy, Crystal N. Holick, Daina B. Esposito et al. · 2015 · BMC Pharmacology and Toxicology
  92. Reevaluating Goals of Insulin Therapy: Perspectives from Large Clinical Trials
    Matthew C. Riddle, Kevin C.J. Yuen · 2012 · Endocrinology and Metabolism Clinics of North America
  93. Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis
    Shangyu Chai, Ruya Zhang, Ye Zhang, Richard David Carr, Yiman Zheng, Swapnil N. Rajpathak, Linong Ji · 2022 · Frontiers in Endocrinology
  94. Diabetes and Coronary Heart Disease
    Graham T. McMahon · 2011 · Springer eBooks
  95. Type 2 Diabetes Treatment Recommendations Update: Appropriate Use of Dipeptidyl Peptidase-4 Inhibitors
    Susan A. Cornell · 2014 · Journal of Diabetes & Metabolism
  96. Efficacy and Safety of DPP-4 Inhibitors and Metformin Combinations in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis
    Rongping Chen, Jing Li, Danqi Chen, Weiheng Wen, Susu Zhang, Jitong Li, Yuting Ruan, Zhen Zhang, Jia Man Sun, Hong Chen · 2024 · Diabetes Metabolic Syndrome and Obesity
  97. Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes
    Deborah A. Hinnen · 2015 · The Science of Diabetes Self-Management and Care
  98. Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Chinese Subjects
    Anders Gummesson, Haiyan Li, Michael S. Gillen, John Xu, Mohammad Niazi, Boaz Hirshberg · 2014 · Clinical Drug Investigation
  99. Analysis of Metformin and Five Gliptins in Counterfeit Herbal Products: Designs of Experiment Screening and Optimization
    Wadhah Atef Salem, Ehab Farouk Elkady, Marwa A. Fouad, Mohammad Abdul‐Azim Mohammad · 2021 · Journal of AOAC International
  100. Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as combination therapy with metformin in the treatment of type 2 diabetes mellitus without established cardiovascular disease in Colombia
    Pieralessandro Lasalvia, Yaneth Gil-Rojas, Ángel Alberto García Peña · 2022 · Expert Review of Pharmacoeconomics & Outcomes Research